Q1 EPS Forecast for Xenon Pharmaceuticals Reduced by Analyst

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities research analysts at Wedbush dropped their Q1 2025 earnings per share estimates for shares of Xenon Pharmaceuticals in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings per share of ($0.87) for the quarter, down from their prior forecast of ($0.84). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share. Wedbush also issued estimates for Xenon Pharmaceuticals’ Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.94) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.68) EPS, FY2026 earnings at ($4.23) EPS, FY2027 earnings at ($3.43) EPS and FY2028 earnings at $1.42 EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.01. During the same quarter last year, the company posted ($0.73) earnings per share.

Several other research firms have also recently weighed in on XENE. Raymond James reiterated an “outperform” rating and issued a $50.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Finally, Needham & Company LLC restated a “buy” rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Xenon Pharmaceuticals has an average rating of “Buy” and a consensus target price of $56.00.

Xenon Pharmaceuticals Price Performance

Shares of Xenon Pharmaceuticals stock opened at $39.95 on Monday. The firm has a fifty day moving average price of $40.20 and a two-hundred day moving average price of $40.82. Xenon Pharmaceuticals has a fifty-two week low of $35.53 and a fifty-two week high of $50.99. The company has a market cap of $3.05 billion, a PE ratio of -14.17 and a beta of 1.20.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Blue Trust Inc. raised its position in Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 641 shares during the last quarter. Avior Wealth Management LLC acquired a new stake in shares of Xenon Pharmaceuticals in the fourth quarter valued at $101,000. nVerses Capital LLC bought a new position in shares of Xenon Pharmaceuticals in the third quarter valued at about $102,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Xenon Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 487 shares during the last quarter. Finally, KBC Group NV lifted its position in Xenon Pharmaceuticals by 39.8% during the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 780 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Gary Patou sold 4,891 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total transaction of $200,922.28. Following the sale, the director now directly owns 23,573 shares of the company’s stock, valued at approximately $968,378.84. The trade was a 17.18 % decrease in their position. The disclosure for this sale can be found here. 5.52% of the stock is currently owned by insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.